RxDoctor Payments Data

Christian Koelbl

Interventional Cardiology · Miami Beach, FLNPI 1245460526

Payments from drug & device makers

$2,362in general payments, 2019–2025

Across 53 payments — averaging $44.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$489
  • Abbott$488
  • Cardiovascular Systems Inc.$243
  • Boston Scientific$217
  • AstraZeneca$161
  • Abiomed$146
  • plus $618 from 16 others

What the payments were for

  • Food & beverage$2,362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,362 in reported general payments places this provider in the 15th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$226,492
Medicare patients
490
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$100,805
EntrestoSacubitril/Valsartan48$46,471
XareltoRivaroxaban19$19,395
Repatha SureclickEvolocumab14$7,814
Metoprolol Succinate146$1,410
Rosuvastatin Calcium116$1,145
Atorvastatin Calcium158$1,138
Losartan Potassium147$1,044
Amlodipine Besylate152$1,031
ClopidogrelClopidogrel Bisulfate82$846
Ezetimibe41$819
Chlorthalidone24$575
Labetalol Hcl22$471
Torsemide17$417
Lisinopril55$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$100,805130 claims
NovartisEntresto$36$46,47148 claims
Johnson & JohnsonXarelto$54$19,39519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →